Arsenic exposure and hypertension: A systematic review

Environmental Health Perspectives

Volumn 120, Issue 4, 2012, Pages 494-500

  Abhyankar, Lalita N ^a   Jones, Miranda R ^a,b   Guallar, Eliseo ^b,c,d   Navas Acien, Ana ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Arsenic; Blood pressure; Hypertension; Meta analysis; Systematic review

Indexed keywords

ARSENIC;

DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; HUMAN; HYPERTENSION; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; WATER CONTAMINATION;

ARSENIC; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING WATER; ENVIRONMENTAL EXPOSURE; HUMANS; HYPERTENSION; PREVALENCE;

EID: 84859335701     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1103988     Document Type: Review

References (54)

1. Aposhian HV, Zakharyan RA, Avram MD, Kopplin MJ, Wollenberg ML. 2003. Oxidation and detoxification of trivalent arsenic species. Toxicol Appl Pharmacol 193:1-8.
2. Appel LJ, Robinson KA, Guallar E, Erlinger T, Masood SO, Jehn M, et al. 2002. Utility of blood pressure monitoring outside of the clinic setting. Evid Rep Technol Assess (Summ) (63):1-5.
3. Balakumar P, Kaur T, Singh M. 2008. Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. Toxicology 245:49-64.
4. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. 1996. Arsenic induces oxidant stress and NF-κB activation in cultured aortic endothelial cells. Free Radic Biol Med 21:783-790.
5. Barchowsky A, Roussel RR, Klei LR, James PE, Ganju N, Smith KR, et al. 1999. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol 159:65-75.
6. Bunderson M, Coffin JD, Beall HD. 2002. Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicol Appl Pharmacol 184:11-18.
7. Carmignani M, Boscolo P, Castellino N. 1985. Metabolic fate and cardiovascular effects of arsenic in rats and rabbits chronically exposed to trivalent and pentavalent arsenic. Arch Toxicol Suppl 8:452-455.
8. Chappell WR, Abernathy CO, Calderon RL, Thomas DJ, eds. 2002. Arsenic Exposure and Health Effects V: Proceedings of the Fifth International Conference on Arsenic Exposure and Health Effects. Amsterdam:Elsevier.
9. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, et al. 1995. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53-60.
10. Chen JW, Chen HY, Li WF, Liou SH, Chen CJ, Wu JH, Wang SL. 2011. The association between total urinary arsenic concentration and renal dysfunction in a community-based population from central Taiwan. Chemosphere 84:17-24.
11. Chen Y, Factor-Litvak P, Howe GR, Graziano JH, Brandt-Rauf P, Parvez F, et al. 2007. Arsenic exposure from drinking water, dietary intakes of B vitamins and folate, and risk of high blood pressure in Bangladesh: a population-based, cross-sectional study. Am J Epidemiol 165:541-552.
12. Chen Y, Graziano JH, Parvez F, Liu M, Slavkovich V, Kalra T, et al. 2011. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. BMJ 342:d2431; doi:10.1136/bmj.d2431 [Online 5 May 2011].
13. Chilvers DC, Peterson PJ. 1987. Global cycling of arsenic. In: Lead, Mercury, Cadmium and Arsenic in the Environment (Huthcinson TC, Meema KM, eds). Chichester:John Wiley & Sons, 279-303.
14. Dastgiri S, Mosaferi M, Fizi MA, Olfati N, Zolali S, Pouladi N, et al. 2010. Arsenic exposure, dermatological lesions, hypertension, and chromosomal abnormalities among people in a rural community of northwest Iran. J Health Popul Nutr 28:14-22.
15. DHHS (Department of Health and Human Services). 2005. Toxicological Profile for Arsenic. Washington, DC:U.S. DHHS.
16. Druwe IL, Vaillancourt RR. 2010. Influence of arsenate and arsenite on signal transduction pathways: an update. Arch Toxicol 84:585-596.
17. Guo JX, Hu L, Yand PZ, Tanabe K, Miyatalre M, Chen Y. 2007. Chronic arsenic poisoning in drinking water in Inner Mongolia and its associated health effects. J Environ Sci Health A Tox Hazard Subst Environ Eng 42:1853-1858.
18. Higgins JP, Thompson SG. 2002. Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558.
19. Hinkle SR, Polette DJ. 1999. Arsenic in Ground Water of the Willamette Basin, Oregon. Portland, OR:U.S. Geological Survey, U.S. Department of the Interior.
20. Houston MC. 2007. The role of mercury and cadmium heavy metals in vascular disease, hypertension, coronary heart disease, and myocardial infarction. Altern Ther Health Med 13:S128-S133.
21. Hsueh YM, Chung CJ, Shiue HS, Chen JB, Chiang SS, Yang MH, et al. 2009. Urinary arsenic species and CKD in a Taiwanese population: a case-control study. Am J Kidney Dis 54:859-870.
22. Hsueh YM, Lin P, Chen HW, Shiue HS, Chung CJ, Tsai CT, et al. 2005. Genetic polymorphisms of oxidative and antioxidant enzymes and arsenic-related hypertension. J Toxicol Environ Health A 68:1471-1484.
23. Huang YK, Tseng CH, Huang YL, Yang MH, Chen CJ, Hsueh YM. 2007. Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan. Toxicol Appl Pharmacol 218:135-142.
24. Jensen GE, Hansen ML. 1998. Occupational arsenic exposure and glycosylated haemoglobin. Analyst 123:77-80.
25. Jones MR, Tellez-Plaza M, Sharrett AR, Guallar E, Navas-Acien A. 2011. Urine arsenic and hypertension in US adults: the 2003-2008 National Health and Nutrition Examination Survey. Epidemiology 22:153-161.
26. Klahr S. 2001. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant 16(suppl 1):60-62.
27. Kwok RK. 2007. A review and rationale for studying the cardiovascular effects of drinking water arsenic in women of reproductive age. Toxicol Appl Pharmacol 222:344-350.
28. Kwok RK, Mendola P, Liu ZY, Savitz DA, Heiss G, Ling HL, et al. 2007. Drinking water arsenic exposure and blood pressure in healthy women of reproductive age in Inner Mongolia, China. Toxicol Appl Pharmacol 222:337-343.
29. Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E. 2009. Serum selenium concentrations and hypertension in the US population. Circ Cardiovasc Qual Outcomes 2:369-376.
30. Lee MY, Jung BI, Chung SM, Bae ON, Lee JY, Park JD, et al. 2003. Arsenic-induced dysfunction in relaxation of blood vessels. Environ Health Perspect 111:513-517.
31. Lee PC, Ho IC, Lee TC. 2005. Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol Sci 85:541-550.
32. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. 1999. Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect 107:359-365.
33. Longnecker MP, Berlin JA, Orza MJ, Chalmers TC. 1988. A meta-analysis of alcohol consumption in relation to risk of breast cancer. JAMA 260:652-656.
34. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. 2006. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747-1757.
35. Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O'Connor GT, et al. 1992. The primary prevention of myocardial infarction. N Engl J Med 326:1406-1416.
36. Medrano MA, Boix R, Pastor-Barriuso R, Palau M, Damian J, Ramis R, et al. 2010. Arsenic in public water supplies and cardiovascular mortality in Spain. Environ Res 110:448-454.
37. Mukherjee A, Sengupta MK, Hossain MA, Ahamed S, Das B, Nayak B, et al. 2006. Arsenic contamination in groundwater: a global perspective with emphasis on the Asian scenario. J Health Popul Nutr 24:142-163.
38. Murray CJ, Lopez AD. 1997. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349:1269-1276.
39. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. 2007. Lead exposure and cardiovascular disease-a systematic review. Environ Health Perspect 115:472-482.
40. Navas-Acien A, Schwartz BS, Rothenberg SJ, Hu H, Silbergeld EK, Guallar E. 2008. Bone lead levels and blood pressure endpoints: a meta-analysis. Epidemiology 19:496-504.
41. Navas-Acien A, Sharrett AR, Silbergeld EK, Schwartz BS, Nachman KE, Burke TA, et al. 2005. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol 162:1037-1049.
42. Oparil S, Zaman MA, Calhoun DA. 2003. Pathogenesis of hypertension. Ann Intern Med 139:761-776.
43. Pi J, Kumagai Y, Sun G, Yamauchi H, Yoshida T, Iso H, et al. 2000. Decreased serum concentrations of nitric oxide metabolites among Chinese in an endemic area of chronic arsenic poisoning in Inner Mongolia. Free Radic Biol Med 28:1137-1142.
44. Rahman M, Tondel M, Ahmad SA, Chowdhury IA, Faruquee MH, Axelson O. 1999. Hypertension and arsenic exposure in Bangladesh. Hypertension 33:74-78.
45. Smedley PL, Kinniburgh DG. 2002. A review of the source, behaviour and distribution of arsenic in natural waters. Appl Geochem 17:517-568.
46. Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, Guallar E. 2008. Cadmium exposure and hypertension in the 1999-2004 National Health and Nutrition Examination Survey (NHANES). Environ Health Perspect 116:51-56.
47. Tsai SH, Liang YC, Chen L, Ho FM, Hsieh MS, Lin JK. 2002. Arsenite stimulates cyclooxygenase-2 expression through activating IκB kinase and nuclear factor κB in primary and ECV304 endothelial cells. J Cell Biochem 84:750-758.
48. Vaziri ND. 2008. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol 295:H454-H465.
49. Wang CH, Hsiao CK, Chen CL, Hsu LI, Chiou HY, Chen SY, et al. 2007. A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. Toxicol Appl Pharmacol 222:315-326.
50. Wang SL, Chang FH, Liou SH, Wang HJ, Li WF, Hsieh DP. 2007. Inorganic arsenic exposure and its relation to metabolic syndrome in an industrial area of Taiwan. Environ Int 33:805-811.
51. Whitworth JA. 2003. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983-1992.
52. Wu MM, Kuo TL, Hwang YH, Chen CJ. 1989. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 130:1123-1132.
53. Yildiz A, Karaca M, Biceroglu S, Nalbantcilar MT, Coskun U, Arik F, et al. 2008. Effect of chronic arsenic exposure from drinking waters on the QT interval and transmural dispersion of repolarization. J Int Med Res 36:471-478.
54. Zierold KM, Knobeloch L, Anderson H. 2004. Prevalence of chronic diseases in adults exposed to arsenic-contaminated drinking water. Am J Public Health 94:1936-1937.